An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and

independent activation of ErbB-3/Akt signaling.

Sala G, Traini S, D’Egidio M, Vianale G, Rossi C, Piccolo E, Lattanzio R, Piantelli M, Tinari N, Natali PG, Muraro R, Iacobelli S

Oncogene 8:1275-86 (2012)

LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.

Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, La Sorda R, Spinella F, Bagnato A, Lattanzio R, D’Egidio M, Di Risio A, Stampolidis P, Piantelli M, Natoli C, Ullrich A, Iacobelli S.

J Mol Med 91:83-94 (2013)

Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.

Sara Traini, Enza Piccolo, Nicola Tinari, Cosmo Rossi, Rossana La Sorda, Francesca Spinella, Anna Bagnato, Rossano Lattanzio, Maurizia D’Egidio, Annalisa Di Risio, Federica Tomao, Antonino Grassadonia,Mauro Piantelli, Clara Natoli and Stefano Iacobelli.

Mol Cancer Ther. 3: 916-925 (2014)

An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis.

Galit Yahalom, Daria Weiss, Ilya Novikov, Therese B. Bevers, Laszlo G. Radvanyi, Mei Liu, Benjamin Piura, Stefano Iacobelli, Maria T. Sandri, Enrico Cassano, Tanir M. Allweis,Arie Bitterman, Pnina Engelman, Luis M. Vence and Marvin M. Rosenberg

Biomarkers in Cancer 5: 71-80 (2013)

LGALS3BP, lectin galactoside-binding soluble 3 binding protein promotes oncogenic cellular events impeded by antibody intervention.

Pavlos Stampolidis, Axel Ullrich, and Stefano Iacobelli

Oncogene 34:39-52 (2015)

EV20, a Novel Anti ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.
Sala G, Rapposelli IG, Ghasemi R, Piccolo E, Traini S, Capone E, Rossi C, Pelliccia A, Di Risio A, D?Egidio M, Tinari N, Muraro R, Iacobelli S

Transl Oncol 6: 676-84 ( 2013)

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.

Ghasemi R, Rapposelli IG, Capone E, Rossi C, Lattanzio R, Piantelli M, Sala G. Iacobelli S.

Oncogenesis 18;3:e117 (2014).

Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer.

Lattanzio R, Ghasemi R, Brancati F, Sorda R, Tinari N, Perracchio L, Iacobelli S, Mottolese M, Natali P, Piantelli M

Oncogenesis (2014) S3:e118. doi: 10.1038.

Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.

Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, Iacobelli S, Holland JD, Birchmeier W, Yu D, Da Silva L, Simpson PT, Khanna K, Chenevix-Trench G and Lakhani SR.

Oncotarget (2015);6:3932-46

ErbB-3 activation by NRG-1 sustains growth and promotes Vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs)

Pramudita R Prasetyanti, Emily Capone, Daniela Barcaroli, Daniela D’Agostino, Silvia Volpe, Antonina Benfante, Sander van Hooff, Valentina Iacobelli, Cosmo Rossi, Stefano Iacobelli, Jan Paul Medema, Vincenzo De Laurenzi and Gianluca Sala

Oncotarget 6:16902-11 (2015).

Prognostic relevance of LGALS3BP in human colorectal carcinoma

Enza Piccolo, Nicola Tinari, Domenica D’Addario, Cosmo Rossi, Valentina Iacobelli, Rossana La Sorda,
Rossano Lattanzio, Maurizia D’Egidio, Annalisa Di Risio, Mauro Piantelli1, Pier Giorgio Natali and Stefano Iacobelli

J Transl Med (2015) 13:248

HER-3: hub for escape mechanisms

Emily Capone, Pramudita R Prasetyanti, and Gianluca Sala

AGING, November 2015, Vol. 7 No.11

Overexpression of PY1289‑HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants

Rossano Lattanzio, Serena Veschi, Gitana Maria Aceto, Maria Cristina Curia, Alessandro Cama, Laura De Lellis, Fabiana Fantini, Domenico Angelucci, Stefano Iacobelli, Mauro Piantelli, and Pasquale Battista

Oncol Lett 12: 453-458, 2016

Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer

Gabriele Corda, Gianluca Sala, Rossano Lattanzio, Manuela Iezzi, Michele Sallese, Giorgia Fragassi, Alessia Lamolinara, Hasan Mirza, Daniela Barcaroli, Sibylle Ermler, Elisabete Silva, Hemad Yasaei, Robert F Newbold, Paola Vagnarelli, Marcella Mottolese, Pier Giorgio Natali, Letizia Perracchio, Jelmar Quist, Anita Grigoriadis, Pierfrancesco Marra, Andrew N Tutt, Mauro Piantelli, Stefano Iacobelli, Vincenzo De Laurenzi and Arturo Sala

J Pathol 2017; 241: 350–361

Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma
Emily Capone , Enza Piccolo , Imma Fichera , Paolo Ciufici , Daniela Barcaroli , Arturo Sala , Stefano Iacobelli Vincenzo De Laurenzi , Valentina Iacobelli , Gianluca Sala

Oncotarget. 2017; 8:60368-60377

EV20-Sap, a novel anti-HER-3 Antibody-Drug Conjugate, displays promising antitumor activity in melanoma

Emily Capone, Francesco Giansanti, Sara Ponziani, Alessia Lamolinara, Manuela Iezzi, Annamaria Cimini, Francesco Angelucci, Rossana La Sorda, Vincenzo De Laurenzi, Pier Giorgio Natali, Rodolfo Ippoliti, Gianluca Sala

Oncotarget https://doi.org/10.18632/oncotarget.20728

EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma

Emily Capone, Alessia Lamolinara, Daniela D’Agostino, Cosmo Rossi, Vincenzo De Laurenzi, Manuela Iezzi, Stefano Iacobelli and Gianluca Sala

J Control Release. 2018 Mar 14;277:48-56

Secreted Gal-3 BP is a novel promising target for noninternalizing Antibody-Drug Conjugates

Francesco Giansanti, Emily Capone, Sara Ponziani, Enza Piccolo, Roberta Gentile, Alessia Lamolinara, Antonella Di Campli, Michele Sallese, Valentina Iacobelli, Annamaria Cimini, Vincenzo De Laurenzi, Rossano Lattanzio, Mauro Piantelli, Rodolfo Ippoliti, Gianluca Sala, Stefano Iacobelli

J Control Release. 2018 Dec 13;294:176-184

HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies.

Lucía Gandullo-Sánchez , Emily Capone , Alberto Ocaña , Stefano Iacobelli , Gianluca Sala and Atanasio Pandiella

EMBO Mol Med. 2020 Apr 24:e11498. doi

Antibody-Drug Conjugates: The New Frontier of Chemotherapy

Sara Ponziani, Giulia Di Vittorio, Giuseppina Pitari, Anna Maria Cimini, Matteo Ardini, Roberta Gentile, Stefano Iacobelli, Gianluca Sala, Emily Capone, David J. Flavell, Rodolfo Ippoliti, Francesco Giansanti

Int J Mol Sci. 2020 Aug; 21(15): 5510

Targeting vesicular LGALS3BP by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma

Emily Capone, Alessia Lamolinara, Fabio Pastorino, Roberta Gentile, Sara Ponziani, Giulia Di Vittorio, Daniela D’Agostino, Sandra Bibbò, Cosmo Rossi, Enza Piccolo, Valentina Iacobelli, Rossano Lattanzio, Valeria Panella, Michele Sallese, Vincenzo De Laurenzi, Francesco Giansanti, Arturo Sala, Manuela Iezzi, Mirco Ponzoni, Rodolfo Ippoliti, Stefano Iacobelli, Gianluca Sala

Cancers (Basel). 2020 Oct 15;12(10):2989

Surface-enhanced Raman scattering (SERS)-based immunosystem for ultrasensitive detection of the 90K biomarker

Valentina Gallo, Antonia Lai, Alessandra Pasquo, Salvatore Almaviva, Stefano Iacobelli, Luca Persichetti, Giovanni Capellini, Giovanni Antonini

Annall Bioanal Chem. 2020 Nov;412(27):7659-7667

EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer

Daniela D’Agostino, Roberta Gentile, Sara Ponziani, Giulia Di Vittorio, Francesco Dituri, Gianluigi Giannelli, Cosmo Rossi, Liberato Marzullo, Francesco Giansanti, Vincenzo De Laurenzi, Stefano Iacobelli, Rodolfo Ippoliti, Emily Capone, Gianluca Sala

Oncol Rep 45, 776-785 (2021)

EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors.

Emily Capone, Rossano Lattanzio, Fabio Gasbarri, Paolo Orsini, Valentina Iacobelli, Vincenzo De Laurenzi, Piergiorgio Natali, Barbara Valsasina, Stefano Iacobelli and Gianluca Sala

Phrmaceutics 2, 483 (2021)

Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target.

Emily Capone, Stefano Iacobelli, Gianluca Sala

J Transì Med 19: 405 (2021)

Increased Gal-3BP plasma levels in hospitalized patients infected with SARS-CoV-2

Valentina Gallo, Team ISERC, Roberta Gentile, Giovanni Antonini, Stefano Iacobelli

Clin Exp Med. 2022 Jan 25:1-5.

Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2 Valentina Gallo, Alyexandra Arienzo, Stefano Iacobelli, Valentina Iacobelli, Giovanni Antonini

Int J Mol Sci. 2022 Jul; 23(13): 7314

Galectin-3 binding protein stimulated IL-6 expression is impeded by antibody intervention in SARS-CoV-2 susceptible cell lines

Mendes-Frias, Valentina Gallo, Valentina Iacobelli, Roberta Gentile, Giovanni Antonini, Ricardo Silvestre, Stefano Iacobelli

Sci Rep 2022, 12: 17047

Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans

Vicencio JM, Evans R, Green R, An Z, Deng J, Treacy C, Mustapha R, Monypenny J, Costoya C, Lawler K, Ng K, De-Souza K, Coban O, Gomez V, Clancy J, Chen SH, Chalk A, Wong F, Gordon P, Savage C, Gomes C, Pan T, Alfano G, Dolcetti L, Chan JNE, Flores-Borja F, Barber PR, Weitsman G, Sosnowska D, Capone E, Iacobelli S, Hochhauser D, Hartley JA, Parsons M, Arnold JN, Ameer-Beg S, Quezada SA, Yarden Y, Sala G, Ng T

Cell Death Dis. 2022 Mar 28;13(3):274.

Extracellular LGALS3BP as potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma

Beatrice Dufrusine, Emily Capone, Sara Ponziani, Rossano Lattanzio, Paola Lanuti, Francesco Giansanti, Vincenzo De Laurenzi; Stefano Iacobelli; Rodolfo Ippoliti, Annunziato Mangiola, Gianluca Trevisi and Gianluca Sala

Mol Oncol 2023 Aug;17(8):1460-1473. doi: 10.1002/1878-0261.13453.

Visualizing Galectin-3 Binding Protein Expression with ImmunoPET

Outi Keinänen, Samantha M. Sarrett, Samantha Delaney, Cindy Rodriguez, Eric J. Dayts, Emily Capone, Frederic Sauniere, Rodolfo Ippoliti, Gianluca Sala, Stefano Iacobelli, Brian M Zeglis

Mol Pharm 2023;20(6):3241-3248.

HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target

Gianluca Sala, Emily Capone, Thordur Tryggvason, Ilaria Cela, Beatrice Dufrusine, Morena Pinti, Francesco Del Pizzo, Helga Sigrún Gunnarsdóttir, Tommaso Grottola, Vincenzo De Laurenzi, Stefano Iacobelli, and Rossano Lattanzio

Cell Death Discovery (2023) 9:400.

Injury-specific factors in the cerebrospinal fluid regulate astrocyte plasticity in the human brain

Sirko S, Schichor C, Della Vecchia, Metzger F, Sonsalla G, Simon T, Bürkle M, Kalpazidou S, Ninkovic J, Masserdotti G, Sauniere JF, Iacobelli V, Iacobelli S, Delbridge C, Hauck SM, Tonn JC and Götz M

Nat Med 2023 12:3149-3161; doi: 10.1038/s41591-023-02644-6.

Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma

Capone E, Perrotti N, Cela R, Togni L, Rubini C, Caponio VCA, Lo Muzio L, Giansanti F, Ippoliti R, Iacobelli S, Spardy N and Gianluca Sala G

Oral Oncol (2024) 123, 106635

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate

Bibbò S, Capone E, Lovato G, Ponziani S, Lamolinara A, Iezzi M, Lattanzio R, Mazzocco K, Morini M, Giansanti F, De Laurenzi V, Whitfield J, Iacobelli S, Ippoliti R, Beaulieu ME, Soucek L, Sala A, Sala G.

J Control Release. 2024 Oct;374:171-180. doi: 10.1016/j.jconrel.2024.08.009. 

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker.

Pece A, Lovato G, Cela I, Mercatelli A, Ferro B, Nikkola J, Pagotto S, Grottola T, De Laurenzi V, Cicchetti R, Marchetti A, Schips L, Lattanzio R, Iacobelli S, Capone E, Black P, Daugaard M, Marchioni M, Sala G.

Mol Oncol. 2025 Oct 5. doi: 10.1002/1878-0261.70140. Online ahead of print.

LGALS3BP antibody-drug conjugate enhances tumor-infiltrating lymphocytes and synergizes with immunotherapy to restrain neuroblastoma growth.

Cela I, Capone E, Pece A, Lovato G, Simeone P, Colasante M, Lamolinara A, Piro A, Iezzi M, Lanuti P, De Laurenzi V, Ippoliti R, Iacobelli S, Sala G.

J Transl Med. 2025 Apr 11;23(1):431. doi: 10.1186/s12967-025-06434-1.